ArticleCase reports in neurological medicine2026
Eosinophilic Granulomatosis With Polyangiitis Presenting With Rare Neurological Manifestations.
Article in Case reports in neurological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare disease characterized by inflammation of small and medium-sized blood vessels, leading to damage in various organs. It is classically associated with asthma, eosinophilia, and multisystem involvement, including frequent peripheral nervous system manifestations. We report the case of a 72-year-old woman with a history of asthma, rhinitis, and strokes, who presented with progressive muscle weakness, myalgia, and distal sensory deficits. Neurological examination revealed proximal muscle weakness and a length-dependent sensory loss. Laboratory investigations demonstrated marked eosinophilia, elevated creatine kinase, and positive antimyeloperoxidase antibodies with an atypical cytoplasmic ANCA pattern. Imaging showed diffuse muscular hypermetabolism on positron emission tomography, while electromyography and nerve conduction studies revealed a length-dependent axonal polyneuropathy with mild myopathic features. Muscle biopsy demonstrated mild nonspecific myopathic changes without definite evidence of vasculitis or eosinophilic infiltrates. Based on the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria, a diagnosis of EGPA with neurological involvement was established. The patient was treated with high-dose corticosteroids and rituximab, resulting in significant clinical and biochemical improvement at 3 months. This case illustrates the coexistence of atypical neurological manifestations of EGPA, including prominent myopathy, length-dependent polyneuropathy, and retrospectively suspected central nervous system vasculitic involvement, emphasizing the importance of early recognition and multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.